journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://read.qxmd.com/read/30935718/response-to-comment-on-synchronous-multiple-non-small-cell-lung-cancers-in-an-allograft-lung-recipient
#1
LETTER
Jean-Louis Pujol, Sébastien Bommart, Pascal Pujol
No abstract text is available yet for this article.
March 26, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30890378/response-to-comment-on-correlation-of-tumor-spread-through-air-spaces-and-clinicopathological-characteristics-in-surgically-resected-lung-adenocarcinomas
#2
LETTER
Min-Shu Hsieh, Mong-Wei Lin
No abstract text is available yet for this article.
March 13, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30878212/corrigendum-to-correlation-of-tumor-spread-through-air-spaces-and-clinicopathological-characteristics-in-surgically-resected-lung-adenocarcinomas-lung-cancer-126-2018-189-193
#3
Szu-Yen Hu, Min-Shu Hsieh, Hsao-Hsun Hsu, Tung-Ming Tsai, Xu-Heng Chiang, Kuan-Chuan Tsou, Hsien-Chi Liao, Mong-Wei Lin, Jin-Shing Chen
No abstract text is available yet for this article.
March 13, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30876688/corrigendum-to-genetic-alterations-of-driver-genes-as-independent-prognostic-factors-for-disease-free-survival-in-patients-with-resected-non-small-cell-lung-cancer-lung-cancer-128-2019-152-157
#4
Akira Ono, Mitsuhiro Isaka, Masakuni Serizawa, Katsuhiro Omae, Hideaki Kojima, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Kenichi Urakami, Takeshi Nagashima, Takashi Sugino, Masatoshi Kusuhara, Toshiaki Takahashi, Ken Yamaguchi, Yasuhisa Ohde
No abstract text is available yet for this article.
March 12, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30879776/what-impacts-the-cost-effectiveness-of-pd-l1-testing-in-non-small-cell-lung-cancer
#5
LETTER
Sara Bravaccini
Programmed Death Ligand 1(PD-L1) testing is recommended for patients with NonSmall Cell Lung Cancer (NSCLC) at stage IIIB and IV, adenocarcinoma and squamous cell carcinoma. Up to now, no clinical-pathological parameters are perfectly able to select a positive PD-L1-patient. For this reason PD-L1 testing is mandatory for patients with advanced NSCLC for whom an immune checkpoint inhibitor treatment is appropriate. Several studies on the cost-effectiveness of immune checkpoint inhibitors in this subset of patients have been published...
March 11, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30979428/comment-on-correlation-of-tumor-spread-through-air-spaces-and-clinicopathological-characteristics-in-surgically-resected-lung-adenocarcinomas
#6
LETTER
Tieniu Song, Lili Jiang, Yidan Lin
No abstract text is available yet for this article.
February 21, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30948150/comment-on-synchronous-multiple-non-small-cell-lung-cancers-in-an-allograft-lung-recipient
#7
LETTER
Christiaan Tji Gan, Erik Verschuuren, Wim van de Bij, Caroline Van De Wauwer, Michiel Erasmus
No abstract text is available yet for this article.
February 19, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885358/pathologic-nodal-clearance-and-complete-response-following-neoadjuvant-chemoradiation-for-clinical-n2-non-small-cell-lung-cancer-predictors-and-long-term-outcomes
#8
Waqar Haque, Vivek Verma, E Brian Butler, Bin S Teh
PURPOSE: From prospective studies, pathologic nodal clearance (PNC, ypN0) and pathologic complete response (pCR, ypT0N0) correlate with overall survival (OS) following neoadjuvant chemoradiation for cN2 non-small cell lung cancer (NSCLC). Contemporary cooperative group trials attempt to increase radiation doses to achieve nodal clearance and/or pCR. However, long-term comparative outcomes of dose-escalated neoadjuvant chemoradiation are lacking. The goal of this study was to evaluate rates of PNC and pCR in a large population of cN2 NSCLC, predictors thereof, and long-term outcomes thereafter...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885357/repeat-biopsy-procedures-and-t790m-rates-after-afatinib-gefitinib-or-erlotinib-therapy-in-patients-with-lung-cancer
#9
Kangkook Lee, Youjin Kim, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Yoon-La Choi, Jong-Mu Sun
OBJECTIVES: Afatinib, a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is used for EGFR-mutant non-small cell lung cancer (NSCLC). However, there are few reports about its resistance mechanisms. The aims of this study are to evaluate resistance mechanisms of afatinib compared with other TKIs and analyze the performance of repeat biopsy which is critical for subsequent treatment. MATERIALS AND METHODS: We screened EGFR-mutant NSCLC patients who started first-line afatinib, gefitinib, or erlotinib from 2014 to 2016, and included patients who acquired resistance...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885356/met-y1003s-point-mutation-shows-sensitivity-to-crizotinib-in-a-patient-with-lung-adenocarcinoma
#10
Yun L Miao, Qing Qing Xu
OBJECTIVES: MET amplification or MET exon 14 skipping site mutation can be treated with crizotinib in non-small cell lung cancer patients. Y1003 is a binding site for E3 ubiquitin ligase, which is critical for MET degradation. Here we show an adenocarcinoma patient with Y1003S mutation and she got tumor remission after crizotinib treatment. MATERIALS AND METHODS: A 61-year-old never-smoking female was admitted to our hospital due to increased carcino-embryonicantigen...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885355/clinical-value-of-neutrophil-to-lymphocyte-ratio-in-patients-with-non-small-cell-lung-cancer-treated-with-pd-1-pd-l1-inhibitors
#11
Tao Jiang, Yuchen Bai, Fei Zhou, Wei Li, Guanghui Gao, Chunxia Su, Shengxiang Ren, Xiaoxia Chen, Caicun Zhou
INTRODUCTION: There is unmet need to explore the predictive biomarkers of PD-1/PD-L1 inhibitors in patients with non-small-cell lung cancer (NSCLC). Here, we aimed to investigate the predictive and prognostic value of blood neutrophil-to-lymphocyte ratio (NLR) in NSCLC patients treated with PD-1/PD-L1 inhibitors. METHODS: We performed a comprehensive online search to explore the association between blood NLR and overall survival (OS) or progression-free survival (PFS) in NSCLC patients received PD-1/PD-L1 inhibitors...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885354/radical-consolidative-treatment-provides-a-clinical-benefit-and-long-term-survival-in-patients-with-synchronous-oligometastatic-non-small-cell-lung-cancer-a-phase-ii-study
#12
Oscar Arrieta, Feliciano Barrón, Federico Maldonado, Luis Cabrera, José Francisco Corona-Cruz, Monika Blake, Laura Alejandra Ramírez-Tirado, Zyanya Lucia Zatarain-Barrón, Andrés F Cardona, Osvaldo García, Osvaldo Arén, Jaime De la Garza
OBJECTIVES: Evidence is rapidly accumulating for the use of radical consolidative treatment (RCT) for patients with oligometastatic non-small cell lung cancer (NSCLC). Nonetheless, published studies have several limitations, including a selection of patients whose favorable characteristics might dictate therapeutic success, as well as scarce prospective data regarding overall survival (OS). The objective of this study was to determine whether RCT increases OS in patients with oligometastatic NSCLC...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885353/pembrolizumab-in-combination-with-ipilimumab-as-second-line-or-later-therapy-for-advanced-non-small-cell-lung-cancer-keynote-021-cohorts-d-and-h
#13
Matthew A Gubens, Lecia V Sequist, James P Stevenson, Steven F Powell, Liza C Villaruz, Shirish M Gadgeel, Corey J Langer, Amita Patnaik, Hossein Borghaei, Shadia I Jalal, Joseph Fiore, Sanatan Saraf, Harry Raftopoulos, Leena Gandhi
OBJECTIVES: Combination immunotherapy may result in improved antitumor activity compared with single-agent treatment. We report results from dose-finding and dose-expansion cohorts of the phase 1/2 KEYNOTE-021 study that evaluated combination therapy with anti‒programmed death 1 (PD-1) antibody pembrolizumab plus anti‒cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody ipilimumab in patients with previously treated advanced non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: Eligibility criteria stipulated histologically/cytologically confirmed advanced NSCLC and treatment failure on ≥1 prior systemic therapy (platinum-based chemotherapy or targeted therapy for patients with EGFR/ALK aberrations)...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885352/mutation-patterns-in-a-population-based-non-small-cell-lung-cancer-cohort-and-prognostic-impact-of-concomitant-mutations-in-kras-and-tp53-or-stk11
#14
Linnéa La Fleur, Elin Falk-Sörqvist, Patrik Smeds, Anders Berglund, Magnus Sundström, Johanna Sm Mattsson, Eva Brandén, Hirsh Koyi, Johan Isaksson, Hans Brunnström, Mats Nilsson, Patrick Micke, Lotte Moens, Johan Botling
OBJECTIVES: Non-small cell lung cancer (NSCLC) is a heterogeneous disease with unique combinations of somatic molecular alterations in individual patients, as well as significant differences in populations across the world with regard to mutation spectra and mutation frequencies. Here we aim to describe mutational patterns and linked clinical parameters in a population-based NSCLC cohort. MATERIALS AND METHODS: Using targeted resequencing the mutational status of 82 genes was evaluated in a consecutive Swedish surgical NSCLC cohort, consisting of 352 patient samples from either fresh frozen or formalin fixed paraffin embedded (FFPE) tissues...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885351/safety-and-efficacy-of-pd-1-inhibitors-in-non-small-cell-lung-cancer-patients-positive-for-antinuclear-antibodies
#15
Yasuto Yoneshima, Kentaro Tanaka, Yoshimasa Shiraishi, Kojiro Hata, Hiroyuki Watanabe, Taishi Harada, Kohei Otsubo, Eiji Iwama, Hiroyuki Inoue, Satohiro Masuda, Yoichi Nakanishi, Isamu Okamoto
OBJECTIVES: To examine the possible effects of antinuclear antibodies (ANA) on the safety and efficacy of programmed cell death-1 (PD-1) inhibitors in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Clinical data including ANA status were reviewed retrospectively for patients with advanced NSCLC who received monotherapy with a PD-1 inhibitor. RESULTS: Of the 83 patients analyzed, 18 (21.7%) were positive for ANA...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885350/efficacy-and-long-term-survival-of-advanced-lung-adenocarcinoma-patients-with-uncommon-egfr-mutations-treated-with-1st-generation-egfr-tkis-compared-with-chemotherapy-as-first-line-therapy
#16
Haixia Li, Chenyu Wang, Ziqi Wang, Yabo Hu, Guowei Zhang, Mina Zhang, Xuanxuan Zheng, Xiaojuan Zhang, Jinbo Yang, Zhiyong Ma, Huijuan Wang
PURPOSE: This study aims to understand the effects and long-term survival of 1st generation epithelial growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)or platinum-based chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations. PATIENTS AND METHODS: Specimens from 4276 advanced (IIIB/IV) patients were diagnosed with lung adenocarcinoma and underwent EGFR gene detection at the Affiliated Cancer Hospital of Zhengzhou University...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885349/high-bin1-expression-has-a-favorable-prognosis-in-malignant-pleural-mesothelioma-and-is-associated-with-tumor-infiltrating-lymphocytes
#17
Tamkin Ahmadzada, Kenneth Lee, Candice Clarke, Wendy A Cooper, Anthony Linton, Brian McCaughan, Rebecca Asher, Stephen Clarke, Glen Reid, Steven Kao
OBJECTIVES: A number of key immune regulators show prognostic value in malignant pleural mesothelioma (MPM), but the association between Bridging integrator 1 (BIN1), indoleamine 2,3 dioxygenase 1 (IDO1) and patient outcome has not been investigated. We aimed to determine the expression of BIN1 and IDO1, their association with other markers and impact on overall survival (OS) in MPM. MATERIALS AND METHODS: The expression of BIN1, IDO1, CD3, CD20 and CD68 were evaluated by immunohistochemistry in 67 patients who underwent pleurectomy/decortication...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885348/pten-inactivation-induces-epithelial-mesenchymal-transition-and-metastasis-by-intranuclear-translocation-of-%C3%AE-catenin-and-snail-slug-in-non-small-cell-lung-carcinoma-cells
#18
Elumalai Perumal, Kim So Youn, Shin Sun, Jung Seung-Hyun, Min Suji, Liu Jieying, Chung Yeun-Jun
OBJECTIVE: Epithelial-mesenchymal transition (EMT) is the key event in distant metastasis of diverse tumors including lung cancer. Recent evidence suggests the involvement of phosphatase and tensin homolog (PTEN) in EMT phenotypes. However, the molecular mechanism of EMT induced by PTEN inactivation is not clear in lung cancer. We aimed to investigate the role of PTEN inactivation in acquisition of EMT in lung cancer cells. METHODS: We knocked out the PTEN in PTEN proficient lung cancer cells lines (A549 and NCI-H460) using CRISPR/Cas-9 system and observed the growth, EMT phenotypes, and EMT related molecules...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885347/treatment-and-outcome-of-432-patients-with-extensive-stage-small-cell-lung-cancer-in-first-second-and-third-line-results-from-the-prospective-german-tlk-cohort-study
#19
Claus-Christoph Steffens, Corinna Elender, Ulrich Hutzschenreuter, Stephanie Dille, Adrian Binninger, Lisa Spring, Martina Jänicke, Norbert Marschner
OBJECTIVES: Despite intensive research, the therapeutic options in extensive-stage small cell lung cancer (SCLC) are still limited. Data from routine clinical practice, so-called "real-world data", are centrally important to assess and improve the standard of care. We present prospectively documented data on systemic first-, second- and third-line treatment, number of treatment lines and outcome parameters of patients treated by medical oncologists in Germany. MATERIALS AND METHODS: This is a descriptive analysis on 432 patients with extensive-stage SCLC enrolled at start of first-line therapy into the prospective German clinical cohort study TLK (Tumour Registry Lung Cancer)...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885346/lung-cancer-mortality-in-australia-in-the-twenty-first-century-how-many-lives-can-be-saved-with-effective-tobacco-control
#20
Qingwei Luo, Julia Steinberg, Dianne L O'Connell, Xue Qin Yu, Michael Caruana, Stephen Wade, Francesca Pesola, Paul B Grogan, Anita Dessaix, Becky Freeman, Sally Dunlop, Peter Sasieni, Tony Blakely, Emily Banks, Karen Canfell
OBJECTIVES: To estimate the number of past and future lung cancer deaths that have already been averted by tobacco control initiatives in Australia, and to estimate the number of additional deaths averted under various smoking scenarios. METHODS: We predicted lung cancer mortality rates and case numbers to 2100 using a previously validated generalized linear model based on age, birth cohort and population cigarette smoking exposure. We estimated the impact of various tobacco control scenarios: 'actual tobacco control' (incorporating the aggregate effect of past and current taxation, plain packaging, mass media campaigns and other initiatives) and scenarios where 10%, 5% and 0% smoking prevalence was achieved by 2025, all of which were compared to a counterfactual scenario with the highest historical smoking consumption level continuing into the future as if no tobacco control initiatives had been implemented...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"